One scan at a time, QyScore® has the potential to revolutionize the treatment of CNS disease and create the potential for earlier precision on the frontlines of CNS disease.

QyScore® is a groundbreaking neuroimaging analysis platform for both clinical routine and clinical trial settings.

Insightful Precision and High Quality Data

Designed to seamlessly integrate with existing workflows, QyScore® provides insightful precision for analysis by offering high-quality data that cannot be found through manual examination of a brain scan alone.

Currently deployed in US & EU clinics (expanding soon into new global markets) and used in multi-site clinical trials and global research collaborations, QyScore® is FDA-Cleared, CE-Marked and Qynapse is ISO-Certified.

Our technology
is a game changer.

Powered by robust technology, our platform produces a wide range of automated measures of neuroinflammation and neurodegeneration, such as whole brain, white matter, grey matter by lobe, cerebellum, white matter abnormalities and brain substructures. To facilitate review by physicians, an automated patient report is rapidly generated after each QyScore® analysis and results are viewable in our proprietary and integrated 3D visualization platform.

QyScore® decreases image reading variability and segmentation errors by 89% and has demonstrated better performance compared to certain other state-of-the-art automated methods on the market, promising precision and accuracy.

Peace of mind for routine and research by providing results you can trust.

 

QyScore® gives clinicians the potential to offer more accurate diagnosis and monitoring for patients, and the potential to bring enhanced trial design, improved patient selection, and endpoint protection to clinical trials. Our platform is cloud-based, easy to use and scales to fit your patient load or trial size.

For Clinical Routine, QyScore®

has the potential to:

Support timely diagnosis

Support disease & therapy monitoring

Support tailored treatment plans

Facilitate therapeutic switching

 

For Clinical Trials

Potential to enhance trial design, improve patient selection and protect imaging endpoints

Automates image pre-processing, quality control and image analysis

FDA-Cleared, CE-Marked platform has the potential to support the contiuum of care from drug development to post-market and long-term monitoring of therapeutic effectiveness and safety.

Main Focus:

Alzheimers and other dementias

Multiple sclerosis

Parkinson’s and movement disorders

These disease areas commonly use imaging and automated measurement techniques to help better characterize patients

In Development:

Ischemic Stroke

Huntington’s Disease

Epilepsy

These disease areas are ones in which we are accumulating data for future use in clinical and research settings.

Traumatic Brain Injury

Schizophrenia

Depression

Transform your Practice.

Qyscore® is a medical device software FDA-cleared – class II and CE-marked – class IIa (CE BSI).

Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore® is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.

Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.